Compare Estee Lauder Companies Inc (EL) vs Novartis AG (NVS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Estee Lauder Companies Inc vs Novartis AG — how do they compare? Estee Lauder Companies Inc trades at $82.83 (market cap $29.78B), while Novartis AG trades at $152.95 (market cap $287.66B). The key difference: Novartis AG is far larger — about 9.7× Estee Lauder Companies Inc's market cap, and Novartis AG pays the higher dividend (3.14%). Which is the better fit depends on your goals.
| EL | NVS | |
|---|---|---|
Market Cap | $29.78B | $287.66B |
Sector | Consumer Staples | Health |
52-Week High | $119.61 | $168.62 |
52-Week Low | $67.23 | $113.50 |
Enterprise Value | $35.95B | $327.68B |
Dividend Yield | 1.7% | 3.14% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Estée Lauder (EL) trades at $82.72, up 2.3% with recent earnings beats but faces fundamental challenges including a negative net income margin of -1.67% and elevated P/E ratio of 147.8. Technical indicators show bearish momentum with support at $81 and resistance at $84. The company maintains strong gross margins at 74.71% and positive analyst sentiment with 44% buy ratings and $90.60 consensus target.
While recent earnings outperformance and strong brand positioning provide upside potential, investors face risks from declining revenue trends, negative profitability, and high valuation multiples. The stock's near-term direction will depend on Q2 2026 earnings delivery and management's ability to restore sustainable growth amid competitive pressures.
NVS trades at $152.51, up 1.43% today, with a bearish technical signal despite strong profitability metrics including a 75.38% gross margin and 35.21% ROE. Recent earnings show mixed results, missing Q1 2026 estimates but beating Q4 2025. The company is actively expanding its oncology pipeline through acquisitions like Myricx Bio for up to $1.5 billion (Reuters, 2026-07-06).
The outlook is balanced; robust cash flow and high margins support growth, but rising debt-to-asset ratios and cautious analyst consensus (68% hold) indicate near-term headwinds. Key risks include execution of pipeline developments and competitive pressures in pharmaceuticals.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Estee Lauder Companies Inc
Estee Lauder is the world leader in the global prestige beauty market, participating across skincare (56% of fiscal 2022 sales), makeup (26%), fragrance (14%), and haircare (4%) categories, with popular brands such as Estee Lauder, Clinique, MAC, La Mer, Jo Malone, Aveda, Bobbi Brown, Too Faced, Origins, Dr. Jart+, and The Ordinary. The firm operates in 150 countries, with 26% of fiscal 2022 revenue stemming from the Americas, 43% from Europe, the Middle East, and Africa, and 31% from Asia-Pacific. The company sells its products through department stores, travel retail, multi-brand specialty beauty stores, brand-dedicated freestanding stores, e-commerce, salons/spas, and perfumeries.
Read more on EL →About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →
